| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor
|
Yan, Junya
|
|
2018
|
89 |
C |
p. 90-101
|
artikel
|
| 2 |
Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?
|
Swets, Marloes
|
|
2018
|
89 |
C |
p. 1-8
|
artikel
|
| 3 |
A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer
|
Nixon, N.A.
|
|
2018
|
89 |
C |
p. 72-81
|
artikel
|
| 4 |
Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?
|
Tong, Yiwei
|
|
2018
|
89 |
C |
p. 9-18
|
artikel
|
| 5 |
Comparing granulocyte colony–stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients
|
Botteri, Edoardo
|
|
2018
|
89 |
C |
p. 49-55
|
artikel
|
| 6 |
Enlisting the willing: A study of healthcare professional–initiated and opt-in biobanking consent reveals improvement opportunities throughout the registration process
|
Fradgley, Elizabeth A.
|
|
2018
|
89 |
C |
p. 36-41
|
artikel
|
| 7 |
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
|
Schneeweiss, Andreas
|
|
2018
|
89 |
C |
p. 27-35
|
artikel
|
| 8 |
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
|
von Moos, Roger
|
|
2018
|
89 |
C |
p. 82-89
|
artikel
|
| 9 |
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors
|
Ameratunga, Malaka
|
|
2018
|
89 |
C |
p. 56-63
|
artikel
|
| 10 |
No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study
|
Lund, Eiliv
|
|
2018
|
89 |
C |
p. 102-112
|
artikel
|
| 11 |
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
|
Lowery, Maeve A.
|
|
2018
|
89 |
C |
p. 19-26
|
artikel
|
| 12 |
Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer
|
Fujii, Takeo
|
|
2018
|
89 |
C |
p. 64-71
|
artikel
|
| 13 |
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO
|
Di Cosimo, S.
|
|
2018
|
89 |
C |
p. 42-48
|
artikel
|
Tijdschrift beschrijving